PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
7.45%
Revenue growth at 50-75% of META's 12.29%. Martin Whitman would worry about competitiveness or product relevance.
7.13%
Gross profit growth at 50-75% of META's 12.33%. Martin Whitman would question if cost structure or brand is lagging.
7.32%
EBIT growth 50-75% of META's 10.27%. Martin Whitman would suspect suboptimal resource allocation.
7.32%
Operating income growth under 50% of META's 16.44%. Michael Burry would be concerned about deeper cost or sales issues.
8.34%
Net income growth at 75-90% of META's 10.17%. Bill Ackman would press for improvements to catch or surpass competitor performance.
-47.37%
Negative EPS growth while META is at 10.47%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-47.37%
Negative diluted EPS growth while META is at 11.04%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.75%
Slight or no buybacks while META is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
0.37%
Slight or no buyback while META is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
5.09%
OCF growth at 75-90% of META's 6.39%. Bill Ackman would demand better working capital management or cost discipline.
-7.60%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
8595.05%
10Y revenue/share CAGR above 1.5x META's 1223.16%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
1552.88%
5Y revenue/share CAGR above 1.5x META's 190.49%. David Dodd would look for consistent product or market expansions fueling outperformance.
250.75%
3Y revenue/share CAGR above 1.5x META's 77.04%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
No Data
No Data available this quarter, please select a different quarter.
1149.71%
5Y OCF/share CAGR above 1.5x META's 653.02%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
185.53%
3Y OCF/share CAGR 1.25-1.5x META's 125.05%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.
11405.35%
Net income/share CAGR above 1.5x META's 2770.56% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
3889.64%
5Y net income/share CAGR above 1.5x META's 304.58%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
200.87%
3Y net income/share CAGR similar to META's 194.47%. Walter Schloss would attribute it to shared growth factors or demand patterns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
503.55%
3Y equity/share CAGR above 1.5x META's 66.56%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.97%
AR growth well above META's 14.10%. Michael Burry fears inflated revenue or higher default risk in the near future.
No Data
No Data available this quarter, please select a different quarter.
8.96%
Asset growth above 1.5x META's 5.19%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
6.47%
1.25-1.5x META's 5.80%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
6.70%
R&D growth drastically higher vs. META's 6.52%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
7.11%
SG&A growth well above META's 12.01%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.